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PAbstract
Background. The positron emission tomography (PET) with F18 17β-estradiol (FES) has good imaging for assessment of estrogen receptor in
breast cancer.
Case. We report on a 30-year-old woman who desired to preserve her fertility with well-differentiated endometrial adenocarcinoma. Before
hormone treatment was started, FES-PET showed increased uptake of endometrium, magnetic resonance imaging (MRI) showed thickness and F-
18 fluorodeoxyglucose (FDG)-PET showed increased uptake. FES-PET after 3 months showed remaining FES uptake, but there were no abnormal
findings on MRI and FDG-PET. Hysteroscopy showed remaining adenocarcinoma. After additional treatment, FES-PET showed a therapeutic
response, and hysteroscopy showed no abnormal finding.
Conclusions. To our knowledge, this is the first report that FES-PET has the potential to provide more useful information than did FDG-PET
about the hormone therapy.
© 2006 Published by Elsevier Inc.37
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CO
RRIntroductionEndometrial cancer is the most common gynecological
malignancy in North American and European women, and the
incidence continues to rise. Mortality from endometrial cancer
ranks eighth among cancer deaths in North American women,
and in Europe nearly 10,000 women die of this disease each
year [1]. For young women (under age 40) who desired to
preserve their fertility with well-differentiated endometrial
adenocarcinoma, conservative treatment with periodic use of
progestin is available [2,3]. Present methods to assess tumor
responsiveness require a tissue sample obtained by performing a
dilatation and curettage (D and C) every 3 months [3]. Sample
availability is thus limited by potential morbidity and sampling
problems. A noninvasive method to assess tumor responsive-
ness would avoid unnecessary diagnostic biopsies of the
endometrium and permit serial assessments during treatment.53
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endometrial cancer, Gynecologic Oncology (2006), doi:10.1016/j.ygyno.2006.10.Positron emission tomography (PET) is a highly sensitive,
noninvasive technology that is ideally suited for pre-clinical and
clinical imaging of cancer biology, in contrast to anatomical
approaches. By using radiolabeled tracers, PET can yield cross-
sectional images that reflect tissue biochemistry [4]. Two
radiolabeled tracers hold promise for the diagnosis and
management of endometrial cancer. The most extensively
studied of these is F-18 fluorodeoxyglucose (FDG); the other
one is F-18 17β-estradiol (FES) [4]. FES-PET has good
imaging characteristics in human studies to predict response to
endocrine treatment in breast cancer [5]. But there has been no
report published on whether FES-PET provides information
useful for assessing tumor response to systemic therapy, or
whether FES-PET provides more useful information than FDG-
PET in endometrial cancer.
Case
We report on an unmarried 30-year-old woman who
presented with well-differentiated adenocarcinoma (Fig. 1A)ith F18 17β-estradiol has the potential to benefit diagnosis and treatment of
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Fig. 1. Histopathology examination of curettaged tissue of endometrium. First curetttaged tissue: (A) hematoxylin and eosin staining showing well-differentiated
endometrial adenocarcinoma (magnification ×400), (B) strong positive immunostaining for estrogen receptor (magnification ×400). Second curetttaged tissue: (A)
hematoxylin and eosin staining showing remaining focal well-differentiated endometrial adenocarcinoma (magnification ×400), (B) moderate positive
immunostaining for estrogen receptor (magnification ×400).
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ARTICLE IN PRESSRRthat an endometrial biopsy showed was predominantly estrogenreceptor (ER) positive (Fig. 1B). She had a history of polycysticovary and had received sequential hormone replacement
therapy (HRT). Because she desired to preserve her fertility,UN
CO
Fig. 2. Endometrial PET during hormonal treatment. Before initiation of treatment: (A
FDG-PET showed slightly increased uptake equivalent to liver uptake. Three mont
endometrium site, but (E) FDG-PET showed no abnormal finding. After additional
Please cite this article as: Yoshida, Y., et al., The positron emission tomography w
endometrial cancer, Gynecologic Oncology (2006), doi:10.1016/j.ygyno.2006.10.medical treatment was desirable. In a recent review of women
under age 40 with well-differentiated adenocarcinoma, con-
servative treatment with periodic use of progestin was used [2],
and informed consent was obtained from a patient. Before) FES-PET showed clearly increased uptake in the endometrium regions and (D)
hs after initiation of treatment, FES-PET showed (B) remaining FES uptake in
treatment, (C) FES-PET showed no abnormal findings.
ith F18 17β-estradiol has the potential to benefit diagnosis and treatment of
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progestin treatment was started in our patient, FES-PET showed
clearly increased uptake in the endometrium regions; the
maximum standardized uptake value (SUV) was 12.5 (Fig.
2A) at late pseudo-secretory phase (day 3 before withdraw
bleeding), magnetic resonance imaging (MRI) showed slight
thickness of endometrium and FDG-PET showed slightly
increased uptake equivalent to liver uptake (Fig. 2B). First,
the patient was treated with medroxyprogesterone acetate
(MPA) 200 mg per day [6,7]. FES-PET after 3 months showed
remaining FES uptake in endometrium site (SUV 6.3) (Fig. 2C),
but there were no abnormal findings on MRI and FDG-PET
(Fig. 2D). Hysteroscopy and endometrial curettage specimens
showed remaining focal well-differentiated adenocarcinoma
(Fig. 1C) with moderate ER positivity (Fig. 1D). Next, she was
treated with MPA 600 mg per day [6,7]. After more than
3 months, FES-PET showed a therapeutic response (Fig. 2E),
and there were no abnormal findings on hysteroscopy and
endometrial curettage specimens.
Discussion
To our knowledge, this is the first report showing that FES-
PET has the potential to provide functional information about
the hormone responsiveness of well-differentiated endometrial
adenocarcinoma. When we performed serial FES-PET imaging
in a woman with well-differentiated adenocarcinoma treated
with MPA, a decrease in FES-PET uptake was seen after a
therapeutic response. This decrease correlated with the
pathological evaluation. Although the pathological evaluation
is the “golden” criteria, FES-PET is a new way to evaluate ER
activity in endometrial adenocarcinoma.
The standard method of assessing uterine neoplasms is the
formal fractional D and C. But to provide sufficient diagnostic
information this method requires that patients are anesthetized
[3]. At present, FDG-PET is not incorporated in routine
clinical practice for diagnosis of gynecologic cancer or
assessment of tumor responsiveness to treatment. However,
current clinical applications of FDG in gynecologic cancer
diagnosis and management have shown many benefits [8]. On
the other hand, the limitation of FDG-PET has been shown to
provide lower diagnostic accuracy in detecting minimal
lesions as well as some pre-forms of cancer and showing no
specificity for cancer detection in general. FDG activity can be
seen in the gastrointestinal tract, bladder and inflammatory
lesions [8,9].
More than 80% of endometrial cancers are usually associated
with a history of unopposed estrogen exposure or other
hyperestrogenic risk factors such as obesity [1]. And, it has
been well documented that the ER level usually is extremely
high especially in well-differentiated endometrial adenocarci-
noma. An increased response rate to hormonal agents, including
progestin, has been associated with positive estrogen or
progesterone receptor status. The PR is a product resultingPlease cite this article as: Yoshida, Y., et al., The positron emission tomography w
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D
PR
OO
F
from estrogen binding to the ER. In some studies, the PR
appears to be a better predictor of hormone responsiveness than
the ER [2]. Yet, the question is whether FES uptake predicts
hormone responsiveness more accurately than does the PR. In
this case, FES-PET provided functional information about
hormone responsiveness in well-differentiated endometrial
adenocarcinoma, similar to that of estrogen dependency of
breast cancer.
It is important to take into consideration the cyclic changes in
estradiol and estrogen receptor when the potential role of FES-
PET in premenopausal women is evaluated because estradiol
increases and progesterone decreases ER expression. In this
case, FES-PET was performed at late pseudo-secretory phase
(day 3 before withdraw bleeding) and showed clearly increased
uptake in the endometrium regions. During the physiological
cycle or during HRT, ER levels are lower in the secretory phase
than in other phases of the cycle [10]. Thus, FES-PET has the
potential to provide functional information about ER activity in
well-differentiated endometrial adenocarcinoma.
In summary, FES-PET showed increased uptake of FES in
well-differentiated endometrial adenocarcinoma and provided
information for assessing tumor response to hormonal therapy;
FES-PET provided more useful information than did FDG-PET.
These observations highlight the need for further systemic
studies on the utility of FES-PET in gynecologic cancer.
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Precis
Usefulness of F18 17β- estradiol PET for endometrial cancer.
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